Innovative Dermatology and Podiatry Brands

 

Medimetriks Pharmaceuticals, Inc. Submits a New Drug Application to FDA for Ozenoxacin Cream, 1%, a Novel Impetigo Treatment 

FAIRFIELD, NJ – June 27, 2016 – Medimetriks Pharmaceuticals, Inc. announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of ozenoxacin cream, 1%, a novel, non-fluorinated quinolone for the treatment of impetigo. Medimetriks licensed exclusive U.S. commercialization rights to ozenoxacin from Ferrer, a leading, privately held Spanish pharmaceutical company, in March 2014 and announced the completion of the second successful Phase 3 pivotal trial in July 2015.

Both Phase 3 pivotal studies demonstrated the superiority of ozenoxacin cream, 1%, applied topically twice daily for 5 days, versus placebo on both the clinical and bacteriological endpoints. In the studies, ozenoxacin demonstrated superior bacteriological cure compared to placebo as early as visit 2 (day 3-4), and showed excellent antibacterial activity against a broad range of bacteria. The studies demonstrated that ozenoxacin was safe and well tolerated in both the adult and pediatric populations aged 2 months and older. Read More

• • • • • • • • • • • • • • • • • •

Knight Breaks Glass on Medimetriks Partnership

MONTREAL and FAIRFIELD, N.J., Feb. 17, 2016 – Knight Therapeutics Inc. (TSX: GUD) (Knight) and Medimetriks Pharmaceuticals, Inc. (Medimetriks) announced today that Knight has issued a secured loan of up to US$20 million to support Medimetriks' acquisition of the exclusive U.S. development and commercialization rights for OPA-15406 from Otsuka Pharmaceutical Co., Ltd., a global healthcare company headquartered in Tokyo, Japan. Read More

• • • • • • • • • • • • • • • • • •

Otsuka Licenses Pre-Phase 3 Topical Atopic Dermatitis Treatment to Medimetriks

  • OPA-15406 is a topical PDE-4 inhibitor being developed for the treatment of atopic dermatitis (AD)

  • OPA-15406 represents a potential best-in-class treatment for the management of AD

  • Otsuka to receive milestone payments including a $22 million upfront payment and Medimetriks to obtain exclusive development and commercialization rights

  • Should OPA-15406 be approved by the U.S. FDA, it will be launched with 250 Medimetriks sales representatives

Tokyo, Japan and Fairfield, New Jersey – February 8, 2016 – Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Medimetriks Pharmaceuticals, Inc. (Medimetriks) today announced that they have entered into a licensing agreement granting Medimetriks exclusive development and commercialization rights for OPA-15406 in the U.S. and Puerto Rico. The agreement also provides manufacturing rights. OPA-15406 is a topical, non-steroidal phosphodiesterase IV (PDE-4) inhibitor, a new treatment class for atopic dermatitis. Read More

• • • • • • • • • • • • • • • • • •

Overview
Medimetriks Pharmaceuticals, Inc. is building a portfolio of innovative Dermatology and Podiatry brands that meet a variety of unmet needs in the marketplace. We seek licensing agreements with companies that are looking to broaden their specialty reach or achieve full-scale commercialization. Our team has experience in planning and achieving NDA approvals, and a history of interaction with a wide range of regulatory agencies, including FDA.

Commercialization Capabilities
We have a proven track record of successfully commercializing brands through strong Marketing and Sales expertise and by building relationships with physicians in both the Dermatology and Podiatry specialties.

Product Focus
We seek to build a pipeline of prescription drug products with strong patent protection by licensing earlier stage products and acquiring commercialized products with remaining patent life.


View our Corporate Presentation

Contact
Alan Goldstein
Executive Vice President, Business Development
Medimetriks Pharmaceuticals, Inc.
383 Route 46 West, Fairfield, NJ 07004
Phone: 973-882-7512, ext. 547 • Fax: 973-882-7502
Email: agoldstein@medimetriks.com